**Appendix 1. Test performance metrics**

**Siemens Healthcare Diagnostics Atellica IM SARS-CoV-2 Total (COV2T)**

**Developer:** Siemens Healthcare Diagnostics
**Test:** Atellica IM SARS-CoV-2 Total (COV2T)
**Technology:** High Throughput CMIA
**Target:** Spike

|  |  |  |  |
| --- | --- | --- | --- |
| Antibody | Performance Measure | Estimate of Performance | 95% Confidence Interval |
| Pan-Ig | Sensitivity (PPA) | 100% (42/42) | (91.6%; 100%) |
| Pan-Ig | Specificity (NPA) | 99.8% (1089/1091) | (99.3%; 99.9%) |

**DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG**

**Developer:** DiaSorin
**Test:** LIAISON SARS-CoV-2 S1/S2 IgG
**Technology:** High Throughput CMIA
**Target:** Spike

|  |  |  |  |
| --- | --- | --- | --- |
| Antibody | Performance Measure | Estimate of Performance | 95% Confidence Interval |
| IgG | Sensitivity (PPA) | 97.6% (40/41) | (87.4%; 99.6%) |
| IgG | Specificity (NPA) | 99.3% (1082/1090) | (98.6%; 99.6%) |

**DiaSorin LIAISON SARS-CoV-2 IgM Assay**

**Developer:** DiaSorin, Inc.
**Test:** DiaSorin LIAISON SARS-CoV-2 IgM Assay
**Technology:** CLIA
**Target:** Spike

|  |  |  |  |
| --- | --- | --- | --- |
| Antibody | Performance Measure | Estimate of Performance | 95% Confidence Interval |
| IgM | Sensitivity | 91.8% (112/122) | (85.6%; 95.5%) |
| IgM | Specificity | 99.3% (2455/2473) | (98.9%; 99.5%) |